LIROH - Liraglutide for Obesity in HIV
- Status
- UnknownResults none
- Why it is watched
- non-weight indication: immune, other_emerging
- Who it enrolls
- age 18 Years to no upper limit; excludes diabetes; BMI ≥30 required; conditions: Obesity; HIV Infections
- Interventions
- Liraglutide
- Conditions
- Obesity; HIV Infections
- Phase and size
- Phase 4 · 40 participants
- Dates
- Start 2024-05-02
Primary completion 2025-05 - Sponsor
- Brigham and Women's Hospital (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Proportion of participants who screen and enroll among those approachedMeasured at screening
- Time to reach study enrollment targetMeasured at enrollment
- Study retention rate at 12 weeksMeasured at Visit 4 at 12 weeks
- Study retention rate at 24 weeksMeasured at End of Study at 24 weeks
- Rate of adherence to treatment over 12 weeksMeasured at Visit 4 at 12 weeks
- Embedded qualitative interviews regarding the acceptability of liraglutide for obesity managementMeasured at End of Study at 24 weeks
02Eligibility
Who can take part
Inclusion Criteria: 1. Able to give written informed consent to participate in the study 2. Able to comply with all study procedures, including daily subcutaneous injections 3. Adults ≥18 years old 4. PLWH on dolutegravir-based ART for ≥6 months 5. Documented HIV-1 viral load in the past 6 months confirming the participant is virologically suppressed 6. BMI ≥30 kg/m2 7. Desiring weight loss 8. Willing to undertake lifestyle change 9. Not on any weight loss agent for the duration of the study Exclusion Criteria: 1. Self-reported history of diabetes 2. Current use of medications for diabetes 3. Known contraindications to liraglutide, such as hypersensitivity to a component of the drug 4. Current pregnancy or desire to become pregnant 5. History of pancreatitis 6. History of thyroid disease 7. History of harmful use of alcohol 8. Clinically unstable in the opinion of the investigator
03Change log
Registry changes
No changes recorded since the trial was added.